WILMINGTON, Del.--(BUSINESS WIRE)--Today, the US Food and Drug Administration (FDA) approved a label update in the US for AstraZeneca’s LOKELMA ® (sodium zirconium cyclosilicate) to include a dosing ...

Objectives: This study examined renin-angiotensin-aldosterone system (RAAS) inhibitor dose levels in a US patient population and investigated the impact of hyperkalemia on RAAS inhibitor dose and the ...

As explained by the National Kidney Foundation, the goal of management of chronic hyperkalemia -- i.e., high levels of potassium in the blood -- is to prevent the development or recurrence of the ...

· Veltassa will be distributed to patients via two nationally-recognized specialty pharmacies · Hospitals will receive Veltassa through a network of authorized specialty distributors · Relypsa's ...

While many healthcare professionals understand the danger of kidney disease, and how critical the organs are in our everyday lives, few understand one of the serious conditions that often occurs when ...

Hyperkalemia treatment trends in the ED are varied and inconsistent, depending on potassium levels when patients reach the ED. Although various treatments decreased potassium over 4 hours, only ...

Approximately 3 million people with chronic kidney disease (CKD) and/or heart failure in the United States have hyperkalemia In clinical trials, Veltassa significantly reduced blood potassium and kept ...

Treatment with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with lower rates of hyperkalemia and a lower rate of renin-angiotensin system inhibitor (RASi) discontinuation ...

Hyperkalemia (high potassium) is a life threatening condition that may be caused by chronic kidney disease, heart failure, dietary intake, or medications like beta-blockers. Research shows people with ...

G_hyperkalemia_web How much do your patients know about the dangers of high potassium levels in the body? They may know that potassium is good for you, or that you need specific levels of it in the ...